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Objective: To evaluate the safety and assess the different symptom improvements 
found after a combined low-frequency primary motor cortex and high-frequency prefron-
tal cortex (PFC) stimulation using the deep TMS (dTMS) H-coil, as an add-on treatment 
for Parkinson’s disease (PD).
Methods: Forty-five PD patients underwent 14 dTMS sessions; each consisting of 1 Hz 
stimulation of the primary motor cortex for 15 min, followed by 10 Hz stimulation of the 
PFC for 15 min. Clinical assessments were performed, BEFORE, at the MIDDLE, and 
END of therapy as well as at FOLLOW-UP after 30  days, using Movement Disorder 
Society-Unified Parkinson’s Disease Rating Scale, TINETTI, UP&GO, SCOPA, HDRS21, 
Beck Depression Inventory, and self-applied daily motor assessment scales.
results: Treatment was well-tolerated, without serious adverse effects. dTMS-induced 
significant PD symptom improvements at END and at FOLLOW-UP, in all subscales of 
the UPDRS, gait speed, depressive symptoms, balance, autonomic symptoms, and a 
73% increase in daily ON time.
conclusion: In the cohort of PD patients treated, dTMS was well-tolerated with only 
minor adverse effects. The dTMS-induced significant improvements in motor, postural, 
and motivational symptoms of PD patients and may potentiate concurrent levodopa 
treatment.
significance: The present study demonstrates that dTMS may have a much wider 
spectrum of beneficial effects than previously reported for TMS, including enhancement 
of levodopa effects, suggesting that future clinical trials with dTMS should include a 
broader range of symptom measurements.
Keywords: Parkinson’s disease, repetitive transcranial magnetic stimulation, h-coil, motor cortex, prefrontal 
cortex, high and low frequency, deep TMs
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introduction
Parkinson’s disease (PD) is a chronic, progressive disorder for 
which there is no satisfactory long-term treatment. The gold 
standard pharmacological treatment for PD is orally adminis-
tered levodopa. Levodopa, while highly effective at controlling 
motor symptoms for a limited time, shows progressive decrease 
in efficacy as the disease progresses. This demands a constant 
increase in dosage to manage symptoms, resulting in a mirrored 
increase in treatment-related adverse effects. This has led to the 
development of several drugs, including dopaminergic agonists, 
which are combined with levodopa to improve PD symptoms and 
control its adverse effects. As the disease progresses, PD symp-
toms and adverse effects re-emerge, highlighting the need for the 
development of novel therapies that can improve PD symptoms 
and related comorbidities.
Focal neuromodulation with repetitive transcranial magnetic 
stimulation (rTMS) has raised increased interest over the past few 
years as a promising coadjuvant treatment for many neurological 
and psychiatric disorders, including PD, as it induces changes in 
cortical excitability non-invasively (1, 2) that persist after stimula-
tion, with cumulative effects over time (3).
Several studies have found that high-frequency stimulation of 
the motor cortex with rTMS (5–10 Hz) improves motor symp-
toms in PD patients (1, 4–9) and produces enduring cortical 
excitation (2, 10–12).
However, several studies have reported that PD patients suffer 
from impaired intra-cortical inhibition (13–17), suggesting that 
low-frequency stimulation of the motor cortex may be more 
beneficial in PD. Indeed, rTMS of the primary motor cortex (M1) 
with low frequencies (0.1–1 Hz) has been shown to produce sig-
nificant improvement in motor symptoms of PD patients (6, 18) 
and long-lasting increases in intra-cortical inhibition (19–21). A 
recent meta-analysis that included eight randomized placebo-
controlled trials that used low frequency rTMS to M1 showed 
significant improvements in PD motor symptoms compared to 
placebo (22).
High-frequency rTMS of the prefrontal cortex (PFC) has also 
been shown to improve motor symptoms (23). This improve-
ment is potentially explained by an increase in striatal dopamine 
release (24).
A new coil for TMS, known as deep TMS H-coil (dTMS) 
designed to stimulate deep cortical areas with lower intensities 
than conventional coils (25) has been reported to induce sig-
nificant improvements in motor symptoms (26) in PD patients. 
The objective of the present study is to retrospectively evaluate 
the effectiveness and safety of dTMS as an add-on treatment for 
PD, using a combination of low frequency (1 Hz) stimulation of 
M1 and high-frequency stimulation of PFC, and to analyze the 




The present study was performed according to the Declaration 
of Helsinki and following a protocol approved by the Ethical 
Committee of the Universidad Andrés Bello (0072015). Forty-
five PD patients (26 men, 19 women) were included in the study 
and attended Neuromagnetics for dTMS treatment between 
October 2012 and September 2014. Each participant signed an 
informed consent. Patients were non-demented adults suffering 
from idiopathic PD, according to previously established clinical 
criteria (27).
The inclusion criteria consisted of a PD diagnosis, pharmaco-
logical treatment with levodopa or dopaminergic agonists, and 
the ability to provide oral or written informed consent. The exclu-
sion criteria included neurological or psychiatric disorders other 
than PD and depression, recent head trauma, personal or family 
history of seizures, presence of metal implants, pacemakers or 
DBS, and uncompensated or non-medicated chronic medical 
conditions (such as hypertension or diabetes).
Deep Transcranial Magnetic stimulation
A dTMS H2 par coil (Brainsway Inc., Israel), designed to 
bilaterally stimulate the complete cortical thickness (25), was 
used with a Rapid2 MagStim stimulator (MagStim Company, 
Ltd., Carmarthenshire, Wales, UK). The total duration of the 
stimulation protocol was 3 weeks. Patients underwent 5 sessions 
of dTMS per week for a total of 12–16 sessions (14 sessions on 
average), and were evaluated at 30 days post-treatment. Each ses-
sion consisted of 16 min of 1 Hz dTMS to M1 and 16 min of 10 Hz 
stimulation to the lateral PFC. For stimulation, the coil was first 
located over the M1 and tilted in the coronal/sagittal planes to a 
position that induced hand movements when stimulated. Resting 
motor threshold (RMT) was determined as the lowest stimula-
tion intensity capable of inducing thumb movement as measured 
by evoked potentials using an EMG of the abductor pollicis brevis 
muscle. Stimulation of M1 was bilateral with stimulus intensity 
set at 110% of RMT (900 stimuli, 90 trains of 10 pulses at 1 Hz, 
1 s inter-train interval). For PFC stimulation, the coil was moved 
6 cm anterior symmetrically from the RMT location and stimula-
tion intensity was set at 100% RMT (1000 stimuli, 50 trains of 20 
pulses at 10 Hz, 18 s inter-train interval). 1 Hz stimulation of M1 
always preceded 10 Hz stimulation of PFC.
clinical Measures
Clinical assessments were performed during patients’ ON state, at 
the same time of day, at baseline (BEFORE), after 6 daily sessions 
(MID), after completion of treatment (END), and 30 days after 
the end of treatment (FOLLOW-UP).
All patients were evaluated with (1) Hoehn and Yahr (H&Y) 
stages evaluation for PD severity (28) and with (2) the Movement 
Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-
UPDRS), including Part I [non-motor activities of daily living 
(ADL)], Part II (motor ADL), Part III (motor examination), and 
Part IV (motor complications) (29). (3) The SCOPA-AUT (30, 
31) to measure autonomic symptoms in PD, including subscales 
for cardiovascular, urinary, sexual, thermoregulation, and gas-
trointestinal dysfunction, (4) the UP&GO to measure gait speed 
(32), (5) the Tinetti for risk of fall (33), (6) the Hamilton Rating 
Scale for Depression (HDRS21) (34), (7) the Beck Depression 
Inventory (BDI) (35) to assess depressive symptoms, and (8) a 
self-assessment of ON&OFF daily periods.
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safety
Patients were asked to report every potential adverse effect, 
including side effects previously associated to TMS or dTMS, 
such as discomfort, headache, toothache, facial ache, seizures, 
pain, cognitive effects, nausea, motor effects/weakness, sleep/
tiredness, and auditory effects (36, 37).
statistical analysis
Statistical analysis was performed using GraphPad Prism v5. All 
patient data were analyzed using a one-way repeated measures 
ANOVA to assess differences between three time-points of testing 
(BEFORE, MID, and END) using TIME as a factor at three levels 
for each scale, except for SCOPA. SCOPA was only measured at 
BEFORE and END and was analyzed using a paired t-test.
Data from the 22 patients that attended the 30-day 
FOLLOW-UP session were used to analyze the post-treatment 
effects of dTMS stimulation with the MDS-UPDRS scale. For 
other scales, data are available from only 16 patients that attended 
the FOLLOW-UP session. A one-way repeated measures ANOVA 
was used to assess the difference between the three time points 
(BEFORE, END, and FOLLOW-UP). The ON&OFF evaluation 
was not measured at FOLLOW-UP.
To test for differences in treatment effects between patients 
who were depressive and those who were not depressive BEFORE 
treatment, patients were divided into two groups; those that had 
seven or less points and those that had more than seven points 
in the HDRS21. A one-way repeated measures ANOVA was used 
to assess the difference between the three time points (BEFORE, 
END, and FOLLOW-UP) for each curve. Then, a two-way 
ANOVA with a Bonferroni post  hoc test was used to assess 
differences between the two curves at each time point. Finally, 
to assess differences in the improvements in motor UPDRS for 
between groups, the difference between BEFORE and END for 
each group was compared between the groups using a paired 
t-test.
To test for differences between gender, physical activity and 
UP&GO improvement, ANOVA was performed with TIME 
(4 levels) and GENDER or SPORT or UP&GO time (2 levels). 
ANOVA was also performed using UP&GO initial severity (time) 
(1 level) and % of improvement in the UP&GO (difference in time 
to perform the task between BEFORE and END). Post hoc com-
parisons were performed using the Bonferroni test. Multivariate 
analysis and possible correlations between initial symptoms, 
motor improvements, and clinical demographics [age, disease 
duration, H&Y scale, levodopa equivalent daily dose (LEDD) and 
baseline motor scores] were analyzed using Spearman’s test. A 
p-value <0.05 was considered statistically significant.
results
Forty-five patients with PD were evaluated and treated with at 
least 12 sessions of dTMS, with an average of 13.6 ± 0.5 sessions. 
The patients were on average 62.5 ± 1.6 years old, had an H&Y 
score of 2.3 ±  0.2 and 9.8 ±  0.9  years since diagnosed. To see 
details of patient demographics see Table 1. Although 32 patients 
returned for assessment 30 days after treatment (FOLLOW-UP) 
and had their MDS-UPDRS evaluation, only 16 of them com-
pleted the evaluation for the other scales. Most patients who 
failed to attend the FOLLOW-UP session reported by phone not 
to have attended because they felt well and preferred to postpone 
treatment sessions while being asymptomatic. Others reported 
being busy and not having sufficient time to attend. From the 
32 patients who attended FOLLOW-UP, 16 were only evaluated 
using the MDS-UPDRS reportedly because they did not have suf-
ficient time that day to complete the other evaluations besides the 
MDS-UPDRS. Average LEDD was 470.72 mg at BEFORE and did 
not change significantly throughout the study, being 478.62 mg 
at END. The medications used were Levodopa (565.2 ± 9.9 mg; 
80% patients); pramipexole (2.2  ±  0.1  mg; 68% of patients); 
hydrochlorothiazide (50 ±  0  mg; 3%); citalopram (20 ±  0  mg; 
8%); Resagiline (1 ± 0 mg; 3%). Three patients were not taking 
medication during treatment.
For a detailed summary of results from all 45 patients, see 
Table 2 and for those patients that attended the FOLLOW-UP 
session see Table 3.
safety
Treatment was well-tolerated with 100% adherence (no drop-outs) 
until the end of treatment. Patients reported only mild and short 
lasting adverse effects; eight patients experienced sleepiness, six 
had headaches during the first sessions and two reported nausea. 
No serious adverse effects were reported.
non-Motor activities of Daily living (non-Motor 
aDl, MDs-UPDrs Part i)
Data showed a strong, significant correlation between time 
(F  =  50.74; p  <  0.0001) and non-motor ADL (Figure  1A), 
with a significant point reduction between BEFORE and MID 
TaBle 1 | Demographics and clinical characteristics of PD patients.
all patients Physical activity no physical activity
all Female Male all Female Male all Female Male
Number of patients 45 19 26 26 12 14 19 7 12
Average age (years) 62.5 ± 1.6 63.7 ± 2.4 61.5 ± 2.1 61.7 ± 2.0 64.4 ± 3.0 59.3 ± 2.6 63.6 ± 2.6 62.6 ± 4.3 64.2 ± 3.4
Average years disease 9.8 ± 0.9 10.4 ± 1.4 9.4 ± 1.1 10.3 ± 1.2 10.9 ± 2.0 9.9 ± 1.6 9.1 ± 1.3 9.4 ± 1.9 8.0 ± 2.4
Average severity 2.6 ± 0.1 2.7 ± 0.2 2.6 ± 0.2 2.4 ± 0.2 2.6 ± 0.2 2.5 ± 0.2 2.7 ± 0.2 2.9 ± 0.5 2.3 ± 0.4
Sessions 13.6 ± 0.5 14.2 ± 0.9 13.1 ± 0.4 13.8 ± 0.8 14.3 ± 1.5 13.3 ± 0.7 13.4 ± 0.4 14.1 ± 0.6 12.5 ± 0.5
The number of patients, their gender, age, years of disease, disease severity (according to Hoehn and Yahr), and number of stimulation sessions are shown for all patients and 
subdivided according to their physical activity (all data shown as average ± SE).
TaBle 2 | summary of results.
N start Middle end p-Value Δ
MDs-UPDrs
Non-motor aspects of activities of daily living 45 11.3 ± 0.9 8.5 ± 0.8 7.1 ± 0.8 <0.0001 4.1 ± 0.5
Motor aspects of activities of daily living 45 16.4 ± 1.1 13.8 ± 1.1 12.2 ± 1.1 <0.0001 4.3 ± 0.5
Motor examination 45 37.0 ± 2.3 34.0 ± 2.5 28.5 ± 2.3 <0.0001 8.7 ± 1.0
Motor complications 45 5.3 ± 0.7 4.3 ± 0.5 4.2 ± 0.5 <0.0001 1.4 ± 0.4
Total 45 70.0 ± 3.8 60.6 ± 4.0 50.8 ± 4.0 <0.0001 20.5 ± 2.4
scOPa-aUT
Gastrointestinal 45 3.2 ± 0.4 – 2.0 ± 0.3 <0.001 1.2 ± 0.3
Urinary 45 3.2 ± 0.5 – 1.7 ± 0.3 <0.0001 1.5 ± 0.3
Cardiovascular 45 3.6 ± 0.5 – 1.7 ± 0.3 <0.0001 2.0 ± 0.4
Thermoregulation 45 2.1 ± 0.4 – 1.6 ± 0.4 >0.05 0.7 ± 0.3
Sexual 45 1.3 ± 0.5 – 1.0 ± 0.4 >0.05 0.1 ± 0.1
Total 45 12.7 ± 1.2 – 7.5 ± 1.0 <0.0001 5.1 ± 0.7
On-Off
ON time (h/day) 14 4.4 ± 1.2 7.2 ± 1.2 7.6 ± 1.2 <0.05 3.2 ± 1.5
OFF time (h/day) 14 10.4 ± 1.3 7.7 ± 1.2 7.2 ± 1.3 <0.05 3.2 ± 1.7
%ON 14 30.4 ± 8.5 48.7 ± 7.5 51.61 ± 8.2 <0.05 21.0 ± 11.1
%OFF 14 69.3 ± 8.6 51.3 ± 7.6 48.3 ± 8.2 <0.05 20.8 ± 11.1
UP&GO 45 17.0 ± 3.7 11.2 ± 0.8 9.7 ± 0.4 <0.05 7.7 ± 3.9
Tinetti
Gait 45 7.6 ± 0.3 9.5 ± 0.2 10.0 ± 0.2 <0.0001 2.3 ± 0.3
Static balance 45 12.0 ± 0.3 14.1 ± 0.3 14.5 ± 0.3 <0.0001 2.6 ± 0.4
BDI 45 10.7 ± 1.2 6.8 ± 0.9 5.4 ± 0.9 <0.0001 5.4 ± 1.0
HDRS-21 45 11.3 ± 1.1 6.5 ± 0.9 5.5 ± 0.9 <0.0001 5.8 ± 1.0
rs
Depressive 25 19.1 ± 1.6 16.2 ± 1.7 14.8 ± 1.7 <0.0001 4.0 ± 1.1
Non-depressive 20 13.1 ± 1.1 10.8 ± 1.0 9.0 ± 0.8 <0.0001 3.1 ± 0.3
Results from the different scales are shown for each time point (Before, Middle and End) for the 45 patients. Significance is shown as *p < 0.05; **p < 0.01; ***p < 0.001; p-value 
and the difference between Before and End time points are also shown. All results appear as average ± SEM.
TaBle 3 | summary of results from patients with 30-day follow-up.
N start end Follow-up p-Value Δ
MDs-UPDrs
Non-motor aspects of activities of daily living 32 11.6 ± 0.9 7.3 ± 0.8 2.9 ± 0.9 <0.0001 8.7 ± 0.8
Motor aspects of activities of daily living 32 15.6 ± 1.2 10.9 ± 0.9 10.8 ± 0.9 <0.0001 4.7 ± 0.6
Motor examination 32 33.1 ± 2.6 24.8 ± 2.2 21.0 ± 2.2 <0.0001 12.1 ± 0.9
Motor complications 32 5.8 ± 0.7 4.1 ± 0.5 4.5 ± 0.6 <0.01 1.3 ± 0.7
Total 32 63.0 ± 4.3 47.1 ± 3.6 39.2 ± 3.6 <0.0001 24.3 ± 1.9
scOPa-aUT
Gastrointestinal 16 3.3 ± 0.7 2.1 ± 0.6 2.6 ± 0.7 <0.05 0.6 ± 0.5
Urinary 16 2.8 ± 0.7 1.4 ± 0.6 1.6 ± 0.7 <0.05 1.1 ± 0.5
Cardiovascular 16 3.6 ± 0.9 1.4 ± 0.5 1.3 ± 0.3 <0.01 2.2 ± 0.7
Thermoregulation 16 1.6 ± 0.5 1.2 ± 0.4 1.0 ± 0.4 >0.05 0.6 ± 0.5
Sexual 9 1.3 ± 0.7 0.9 ± 0.5 0.9 ± 0.4 >0.05 0.4 ± 0.4
Total 16 11.9 ± 1.7 6.6 ± 1.7 7.1 ± 1.5 <0.0001 4.9 ± 1.3
TineTTi
Gait 16 7.3 ± 0.5 10.1 ± 0.3 9.9 ± 0.4 <0.0001 2.4 ± 0.6
Static balance 16 12.0 ± 0.7 14.7 ± 0.4 14.6 ± 0.4 <0.0001 3.2 ± 0.7
BDI 16 9.1 ± 1.6 4.9 ± 1.5 6.3 ± 1.5 <0.01 3.9 ± 0.8
HDRS-21 16 9.3 ± 1.4 3.6 ± 1.5 5.6 ± 0.7 <0.001 4.3 ± 0.6
Results from the different scales are shown for each time point (Before, End and FOLLOW-UP) for the patients who attended the FOLLOW-UP session 30 days after treatment (N 
is number of patients with data and delta corresponds to the change in scale in points). Significance is shown as *p < 0.05; **p < 0.01; ***p < 0.001; p-value and the difference 
between BEFORE and END time points are also shown. All results appear as average ± SEM.
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(11.3  ±  0.9–8.5  ±  0.8 points; p  <  0.001), BEFORE and END 
(11.3 ±  0.9–7.1 ±  0.8 points; p <  0.001), and MID and END 
(8.5 ± 0.8–7.1 ± 0.8 points; p < 0.001). In the case of the patients that 
attended the 30-day, post-treatment FOLLOW-UP (Figure  1E), 
they showed a significant decrease (F  =  8.510; p  <  0.0001) 
from BEFORE to END (11.6 ± 1.0–7.3 ± 0.8 points; p < 0.001), 
between BEFORE and FOLLOW-UP (11.6 ± 1.0–2.9 ± 0.9 points; 
p < 0.001), and from END to FOLLOW-UP (7.3 ± 0.8–2.9 ± 0.9 
points; p  <  0.001), suggesting further improvements 30  days 
post-treatment, beyond the improvements attained by the END 
of treatment.
Motor activities of Daily living  
(Motor aDl, MDs-UPDrs Part ii)
A significant relationship between time (F = 42.07; p < 0.0001) 
and motor ADL was found (Figure  1B). Significant symptom 
improvements were found between BEFORE and MID (from 
16.4 ± 1.2 to 13.8 ± 1.1 points; p < 0.001), between BEFORE and 
END (reduction from 16.4 ± 1.2 to 12.2 ± 1.1 points; p < 0.001), and 
between MID and END (reduction from 13.8 ± 1.1 to 12.2 ± 1.1 
points; p <  0.001). For the group of patients that attended the 
FOLLOW-UP session (Figure  1F), the statistically significant 
improvement between BEFORE and END (F = 18.58; p < 0.0001) 
(reduction from 15.6 ± 1.2 to 10.9 ± 0.9 points; p < 0.001) was 
maintained for over 30 days (BEFORE to FOLLOW-UP; reduc-
tion from 15.6 ± 1.2 to 10.8 ± 0.9 points; p < 0.001), showing no 
significant differences between END and FOLLOW-UP.
Motor examination (MDs-UPDrs Part iii)
A strong correlation between time (F = 24.97; p < 0.0001) and 
motor MDS-UPDRS (Figure 1C) was found. Motor symptoms 
decreased over time and reached significance at the MID and 
END time-points compared to BEFORE [37.0 ± 2.3 (BEFORE) 
to 34.0  ±  2.5 (MID) to 28.5  ±  2.3 (END); p  <  0.001]. At 
FOLLOW-UP patients demonstrated a significant decrease 
FigUre 1 | effects of dTMs in PD measured using the MDs-UPDrs scale. dTMS produced significant improvements in non-motor ADL (a) and motor ADL 
(B) at Middle and End of treatment. (c) dTMS produced a decrease in motor examination (MDS-UPDRS Part III), with a significant reduction at the End of treatment. 
(D) dTMS induced an improvement in motor complications that was significant at the End of treatment. Similar results are shown in a group of patients with 30-day 
Follow-up, in non-motor ADL (e), motor ADL (F), motor examination (g) and motor complications (h), where a significant difference was found in all measures. 
(*p < 0.05; **p < 0.01; ***p < 0.001).
(F = 11.09; p < 0.0001) between BEFORE and END (p < 0.001), 
BEFORE and FOLLOW-UP (p < 0.001), and between END and 
FOLLOW-UP (p < 0.05), decreasing from 33.1 ± 2.6 (BEFORE) 
to 24.8 ±  2.2 (END) and to 21.0 ±  2.2 (FOLLOW-UP). There 
was a tendency for further improvement after treatment, but 
no significant differences between END and FOLLOW-UP 
(Figure  1G). In summary, dTMS treatment correlated with a 
decrease of 8.3 points in the UPDRS-III at END and 12.1 points 
at 30 days FOLLOW-UP. Thus, dTMS was a strong predictor for 
a decrease in PD motor symptoms.
Motor complications (MDs-UPDrs Part iV)
In the present study, patients showed a significant decrease 
(F = 5.35; p < 0.01) in motor complications. A significant differ-
ence was found between BEFORE and MID as well as between 
BEFORE and END (Figure  1D), from 5.3 ±  0.7 (BEFORE) to 
4.3 ± 0.5 (MID) to 4.2 ± 0.5 (FOLLOW-UP) points (p < 0.05; 
p <  0.01). Patients who participated in the follow-up session 
(Figure 1H) showed similar significant symptom improvements 
(F = 4.99; p < 0.01) with a significant difference between BEFORE 
and END (reduction from 5.8 ± 0.7 to 4.1 ± 0.5 points; p < 0.05) 
and a similar decrease between BEFORE and FOLLOW-UP 
(reduction from 5.8 ±  0.7 to 4.5 ±  0.6 points), which was not 
found to be significant. There were no significant differences 
between END and FOLLOW-UP.
UP&gO
As can be seen in Figure 2A the treatment was a significant predic-
tor of improvement in the UP&GO test, as demonstrated by the 
decrease in the time required to complete the task (F = 0.1777; 
p < 0.05), from BEFORE to END (17.0 ± 3.7–9.7 ± 0.4). No dif-
ferences between BEFORE to MID or from MID to END were 
found. Interestingly, improvements were correlated with greater 
severity (R2 = 0.8341) (Figure 2B), although this result may be 
explained by a ceiling effect, as patients cannot improve beyond 
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normality, so patients with larger symptom severity will improve 
more to reach normality than those with less severity.
TineTTi
Patients showed a significant difference in gait balance through-
out treatment (Figure 3A; F = 19.67; p < 0.0001), increasing from 
7.6 ± 0.3 points at BEFORE to 9.5 ± 0.2 at MID (p < 0.0001), and to 
10.0 ± 0.2 at END (p < 0.0001). In addition, there were significant 
differences in static balance (Figure 3B; F = 38.48, p < 0.0001), 
increasing from 12.0 ± 0.3 points at BEFORE, to 14.1 ± 0.3 at 
MID (p < 0.0001), and to 14.5 ± 0.3 at END (p < 0.0001).
The improvement in gait balance was maintained at the 
30-day follow-up session (Figure 3C; F = 13.96; p < 0.0001), with 
significant differences between BEFORE and END (7.3 ±  0.5–
10.1 ± 0.3; p < 0.0001), and between BEFORE and FOLLOW-UP 
FigUre 2 | effects of dTMs on gait speed (UP&gO). (a) dTMS produced a significant decrease in the time taken to stand up and walk 3 m, which was 
significant at the End of treatment, (B) The greater the severity in the UP&GO, the greater the improvements after treatment. A correlation was found between initial 
time in seconds (y axis) and the percentage of Deep TMS improvement (initial/final time, x axis). Regression shows that the higher the severity, the greater the 
improvements (*p < 0.05).
FigUre 3 | effects of dTMs on posture and balance (TineTTi). dTMS produced a significant improvement in posture and balance during gait (a) and while 
standing (B) at the END of the treatment, which were also significant for balance during gait (c) and while standing (D) at FOLLOW-UP (30 days after) (***p < 0.001).
(7.3 ± 0.5–9.9 ± 0.4). Same was found for static balance (Figure 3D; 
F = 4.066; p < 0.0001), in which significant differences between 
BEFORE and END (12.0 ± 0.7–14.7 ± 0.4) and between BEFORE 
and FOLLOW-UP (12.0 ± 0.7–14.6 ± 0.4) were found.
scOPa-aUT
As depicted in Figure  4A (p <  0.0001), a significant decrease 
in SCOPA was found between BEFORE (12.7 ± 1.2) and END 
(7.5 ± 1.0 points, p < 0.001). There was also a significant reduc-
tion in cardiovascular symptoms (Figure 4B; p < 0.0001) from 
BEFORE (3.6 ± 0.5) to END (1.7 ± 0.3). A significant decrease 
in gastrointestinal symptoms was found (Figure 4C; p < 0.0001) 
between BEFORE (3.2 ± 0.6) and END (2.0 ± 0.3). Additionally, 
significant decreases in urinary symptoms were found between 
the BEFORE and END time points (Figure 4D; from 3.2 ± 0.5 to 
FigUre 4 | effects of dTMs effects on autonomic symptoms as measured by scOPa. (a) dTMS produced significant improvements in total SCOPA at END. 
dTMS also induced significant improvements in cardiovascular (B), gastrointestinal (c), urinary (D), and thermoregulation (e) from BEFORE to END, but  
non-significant reductions in (F) sexual symptoms. Significant differences were found at the Follow-up period for Total SCOPA (g) and cardiovascular symptoms (h), 
but not for gastrointestinal (i), urinary (J), thermoregulation (K) and sexual Symptoms (l) (*p < 0.05; **p < 0.01; ***p < 0.001).
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1.7 ± 0.3, p < 0.001). Thermoregulation also showed significant 
improvements (Figure 4E; from 2.1 ± 0.4 to 1.6 ± 0.4, p < 0.001) 
but no significant decreases in sexual symptoms were found 
(Figure 4F).
For patients who attended the follow-up session, the total 
symptom score (Figure  4G; p <  0.0001), showed a significant 
decrease (F = 12.33; p < 0.001) from BEFORE to END and from 
BEFORE to FOLLOW-UP [11.9 ±  2.0 (BEFORE) to 6.5 ±  1.7 
(END) to 7.1 ± 1.5 (FOLLOW-UP), p < 0.001]. There was a signifi-
cant reduction (F = 8.697; p < 0.01) in cardiovascular symptoms 
(Figure 4H) from BEFORE (3.6 ± 0.9) to END (1.4 ± 0.5) and 
to FOLLOW-UP (1.3 ± 0.3). Additionally, a significant decrease 
(F = 4.696; p < 0.05) in gastrointestinal symptoms (Figure 4I) 
between BEFORE (3.3 ± 0.7) and END (2.1 ± 0.6) was found. No 
significant differences were found in gastrointestinal symptoms 
between BEFORE and FOLLOW-UP. Urinary symptoms showed 
a significant decrease at END (F =  3.575; p <  0.05) but not at 
FOLLOW-UP (Figure 4J; from 2.8 ± 0.7 to 1.4 ± 0.6). There was 
a non-significant tendency to improve in both thermoregulation 
(Figure 4K) and sexual symptoms (Figure 4L).
FigUre 5 | effects of dTMs on OFF and On daily periods. dTMS produced (a) a significant increase of ON time per day and (B) a significant decrease in OFF 
time per hour (*p < 0.05).
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On/OFF Daily Periods
Patients were asked to self-assess their daily symptoms and to 
measure ON & OFF periods every 30  min, from 1  week prior 
to treatment (BEFORE), until its end (END). Fourteen patients 
completed the assessment (31% of the patients). There was a 
significant increase in percentage of ON time, from 32.0 ± 0.8 to 
48.0 ± 8.4%/h (see Figure 5A; F = 7.619, p < 0.001) and a signifi-
cant decrease in OFF-time from 68.1 ± 8.0 to 52.0 ± 8.0%/h (see 
Figure 5B; F = 18.96, p < 0.001). The increase from 32 to 48% of 
ON time per hour means a 50% increase in ON time each hour. 
In terms of ON hours per day, patients increased from 4.4 ± 1.2 
to 7.6 ± 1.2 h/day, which corresponds to a 73% increase in total 
ON time per day.
hamilton rating scale for Depression (hDrs21)
Of the 45 patients, 29 (64.4%) scored 7 or more points on the 
HDRS21. This means that 29 patients in the sample were con-
sidered depressed as defined by the physician-applied HDRS21 
(Hamilton) scale. As seen in Figure 6A, there was a significant 
improvement in overall depressive symptoms of all patients, with 
a significant effect of time (F =  27.64; p <  0.0001). There was 
a significant decrease in depressive symptoms from BEFORE 
(11.3 ±  1.1 points) to END (5.5 ±  0.9; p <  0.0001), improve-
ment that was maintained at FOLLOW-UP (5.6 ± 0.7; p < 0.05) 
(Figure  6B). Analysis of depressed patients only (≥7 points) 
showed a significant symptom decrease (F014.55; p <  0.0001) 
from BEFORE (12.9 ± 0.9 points) to END (5.6 ± 1.1; p < 0.001) 
in the HDRS scale. At the END time point, 62% of depressed 
patients experienced symptom remission (<7 points).
Beck Depression inventory
To compare the results of health professional-applied HDRS 
with a self-applied depression scale, the BDI was used. 
Consistent with the results found with the HDRS scale, there 
was also a significant effect of time in depressive symptoms as 
evaluated by the self-assessed BDI scale (F = 25.65; p < 0.0001), 
with a significant decrease from 10.7 ± 1.2 at the BEFORE to 
5.4 ± 0.9 at the END point (Figure 6C). This improvement was 
maintained at the 30 days FOLLOW-UP evaluation [F = 9.539: 
p < 0001; from 9.1 ± 1.6 (BEFORE) to 6.3 ± 1.5 (FOLLOW-UP)] 
(Figure 6D).
Motor improvements in Depressed and  
non-Depressed Patients
To determine whether antidepressant effects may have contrib-
uted to the improvements in motor symptoms, patients’ data 
were divided into two groups; those that did not have depres-
sion (<7 points) and those that had depression (≥  7 points) 
as assessed by the HDRS21 scale. Twenty-five patients showed 
depression and 20 were not depressed according to the HDRS21 
scale. Their data from the motor MDS-UPDRS (Part III) subscale 
were compared within each group and between groups. A strong 
correlation between time and motor MDS-UPDRS (Figure 7A) 
was found for both the depressed (F = 28.53; p < 0.0001) and 
the non-depressed groups (F  =  14.55; p  <  0.0001). For the 
depressed group, motor symptoms decreased over time and 
reached significance at the MID and END time-points com-
pared to BEFORE [19.1 ± 1.6 (BEFORE) to 16.24 ± 1.7 (MID) 
to 14.8 ± 1.7 (END); p < 0.001]. For the non-depressed group, 
motor symptoms decreased over time and reached significance 
at the MID and END time-points compared to BEFORE 
[13.1 ± 1.1 (BEFORE) to 10.8 ± 1.0 (MID) to 9.0 ± 0.8 (END); 
p < 0.001]. Note that depressed patients showed greater symp-
tom severity compared to non-depressed patients, at BEFORE 
(p < 0.001), MIDDLE (p < 0.001), and END (p < 0.001) time 
points. The improvements in both groups in response to treat-
ment were almost identical (Figure 7B), showing no significant 
differences between them (depressed patients, 4.3 ± 0.6 points; 
non-depressed patients, 4.3  ±  0.9 points). In consequence, 
dTMS improvements in motor symptoms were significant and 
similar irrespective of whether patients were depressed or not 
at the beginning of treatment.
correlations Between gender,  
Physical activity, severity, and improvements
Multivariate analysis using the Spearman test showed significant 
correlations between age and initial values of disease severity 
(MDS-UPDRS motor, non-motor ADL, motor ADL, complica-
tions of treatment, UP&GO, and Tinetti). Disease severity 
according to the H&Y, was correlated with years of disease. 
Another correlation was found between initial HDRS and both 
MDS-UPDRS treatment complications and Tinetti. Lastly, a cor-
relation was found between HDRS and ADL at the END time 
FigUre 6 | effects of dTMs on depressive symptoms as measured by hamilton (hDrs21) and Beck Depression inventory (BDi). dTMS produced a 
significant improvement in depressive symptoms, leading to remission (<7 points) according to HDRS at the END (a) and the FOLLOW-UP (B) of the treatment. The 
same results were found with the BDI at the same points [(c) for END and (D) for FOLLOW-UP] (*p < 0.05; **p < 0.01; ***p < 0.001).
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point. The variables age, years of disease or number of sessions 
treated did not correlate with physical activity. For details see 
Table 4.
Discussion
The present study supports the notion that dTMS could be a safe 
and effective adjuvant treatment for PD, yet given the lack of a 
placebo-controlled group, the present study cannot be considered 
a demonstration of treatment efficacy. However, the efficacy of 
low frequency stimulation of the motor cortex with rTMS has 
been demonstrated by several placebo-controlled studies, which 
were analyzed in a recent meta-analysis (22).
This is the first study to evaluate retrospectively the 
effects of dTMS in a clinical setting. This is relevant because 
FigUre 7 | effects of dTMs on motor symptoms depending on previous depression as measured by hamilton (hDrs21). (a) dTMS produced significant 
and similar improvements in motor symptoms in patients with (≥7 points) or without (<7 points) depression according to HDRS score obtained at the BEFORE 
session. (B) Difference between BEFORE and END in both groups was similar in value and not different statistically (*p < 0.05; **p < 0.01; ***p < 0.001 and 
#p < 0.05; ##p < 0.01; ###p < 0.001).
placebo-controlled studies include only a subgroup of patients 
with similar symptom severities, whereas in a clinical setting, 
patients treated show more heterogeneous symptoms, ages, 
and demographics. The present results, based on a cohort of 45 
patients, demonstrate that dTMS using LF stimulation of the M1, 
and HF stimulation of the PFC is a predictor to a wide range 
of significant improvements in PD symptoms, including not 
only motor symptoms, which have been reported previously in 
placebo-controlled studies for rTMS (22), but also in non-motor, 
autonomic and depressive symptoms, and significant improve-
ments in activities of daily living (ADL). Although only 32 
patients participated in the FOLLOW-UP session, their improve-
ments remained significant 30 days after treatment (see Table 1 
for a summary), suggesting that treatment effects lasted at least 
30 days post-treatment.
TaBle 4 | spearman test for multivariate analysis.

























– – – – – – – *** *** – *** –
Final MDS-UPDRS 
motor
– – – – – – * *** *** – * –
Δ MDS-UPDRS 
motor
– – – – – – – – – – * –
Initial UP&GO – – – – – – – – – – – –
Final UP&GO – – – – – – – – – – – –
Δ UP&GO ** – – – – – – – – * – –
Initial HDRS – – – – – *** *** – – – – –
Final HDRS – – – – * *** *** * ** – – –
Initial gastrointestinal 
SCOPA
– – * – – – – – ** – – –
Δ Gastrointestinal 
SCOPA
– – – – – – – – – – * –
Initial urinary SCOPA – – ** – – – – – * * – –
ΔUrinary SCOPA – – ** ** – – – – – * – –
Initial Cardiovascular 
SCOPA
– – – – – – – – * ** * –
Δ Cardiovascular 
SCOPA




* – – – – * * – – – * –
Δ Thermoregulation 
SCOPA
– – – – – – – – – – – –
Initial sexual SCOPA – – – – – – – – – – – –
ΔSexual SCOPA – – * – – – – – – – – –
Initial Total SCOPA – – – – – – * – ** – *** –
Δ Total SCOPA – – – – * – – – – – – –
Initial gait tinetti – – – – – – – – – – – –
Δ gait tinetti – – – – – – * – – – – –
Initial static tinetti – – – – – * – – – * * –
Δ static tinetti – – – – – – – – – – ** –
Correlations are shown as “*”; no correlation as “–” (*p < 0.05; **p < 0.01; ***p < 0.001).
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In the recently published meta-analysis that included eight 
placebo-controlled trials, LF rTMS was reported to be an effective 
adjuvant for the treatment of motor symptoms in PD, with an 
average improvement of 5.05 points in the UPDRS part III (22). 
In the present study, the average decrease in motor symptoms 
according to the MDS-UPDRS part III subscale was 8.5 points 
at the END of treatment and 8.6 points 30 days after treatment. 
The UPDRS is among the most accepted scales available for PD 
symptom evaluation (29).
Perhaps one of the most important results of the present study 
is the wide range of symptoms that benefit from dTMS treatment, 
suggesting that the improvements are not only limited to the 
motor symptoms included in MDS-UPDRS (III). This suggests 
that other symptoms could be measured in clinical trials assessing 
dTMS for PD treatment. For example, the risk of fall, which is 
common in PD patients and may lead to the need of a walking aid, 
significantly decreased thereby rendering those aids unnecessary 
in several patients, affording them the ability, for example, to 
climb stairs safely.
The present results also suggest that patients benefit from 
treatment irrespective of disease severity, especially when meas-
uring improvements in the UP&GO scale [which measures gait 
speed (32)]. The improvements in response to treatment were 
larger for patients with greater severity, which may be explained 
by a ceiling effect, as patients with low disease severity have fewer 
symptoms and thus, less potential for improvement to reach 
normality, than those suffering from greater disease severity. 
It is interesting to note that, previous studies using fMRI have 
shown that rTMS-related improvements in mid-gait freezing 
are correlated with increased caudate activity and with changes 
in functional connectivity between PFC and supplementary 
motor area (9).
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The present improvements in autonomic symptoms as meas-
ured by SCOPA are consistent with previous studies showing 
that LF rTMS in M1 or HF in PFC may affect the autonomic 
system (38), whereas HF in PFC may improve autonomic cardiac 
dysfunctions linked to depression (39). Our findings further sup-
port a possible relationship between the autonomic system and 
LF rTMS in M1 or HF in PFC.
In terms of depressive symptoms, the self-administered BDI 
scale was used to contrast patients’ self-perception of mood and 
depressive symptoms, with clinician-applied HDRS21. Both scales 
revealed significant improvements, reaching remission in 62% of 
depressed patients (18 out of 29 depressed patients). This antide-
pressant effect may be the result of motor symptom improvement, 
as the multivariate analysis showed a correlation between HDRS 
and ADL at END, suggesting that greater improvements in ADL 
may lead to greater improvements in depression. However, a pre-
vious clinical trial evaluated the benefit of rTMS in PD patients 
with depressive symptoms, with HF stimulation targeting the left 
PFC (40) to obtain antidepressant effects. Thus, it is also possible 
that in the present study the bilateral HF stimulation of PFC 
contributed to the treatment antidepressant effects.
This raises the question of whether the improvements in 
motor symptoms obtained here after dTMS can be attributed to 
antidepressant effects. To answer this question, we compared the 
improvement of patients that initiated the treatment with and 
without depression. Our results show that although depressed 
patients show in average greater motor symptom severity, their 
improvements are similar to those obtained in patients without 
depression, at least for the motor UPDRS. This suggests that 
motor symptom improvements after dTMS are significant and 
similar irrespective of depressive symptoms. This does not rule 
out a contribution of antidepressant effects, but demonstrates that 
motor symptom improvements after dTMS cannot be attributed 
to antidepressant effects, as patients without depression have 
similar symptom improvements as those with depression.
Two key factors to be considered in PD studies are time of 
day and the patients’ emotional state when symptoms are being 
measured. In this study, measurements could not be performed 
during OFF periods as patients ranged from those experiencing 
<10% of the day OFF, to those experiencing full day OFF. Patients 
with 100% OFF response to Levodopa were included in the pre-
sent study only if diagnosed with PD and had been responsive to 
the drug earlier in their disease. Measurements were taken at the 
same time of day in all patients, during an ON period, unless the 
patient experienced no ON periods, in which case measurements 
were taken at the time most comfortable to the patient. To ensure 
that measurements did reflect the patient’s motor symptoms 
throughout the day, they were given a self-applied scale for 
ON&OFF periods with questions to be answered every 30 min. 
Adherence to scale completion reached 30%, and resulted in two 
major findings. First, there was a significant and large increase in 
daily ON time, incrementing from 4.4 ± 1.2 to 7.6 ± 1.2 h/day, a 
42% increase. Second, 5 patients began treatment with 100% OFF 
time (without ON time) and by the end of treatment, 3 of those 
patients had gained ON periods, increasing in average from 0 to 
6.3 h/day. This implies that there was a significant improvement 
in the amount of ON hours per day independently of the time of 
measurement, suggesting that dTMS may potentiate the effect of 
Levodopa. There were no changes in pharmacotherapy before or 
during treatment. Although dyskinesia decreased in average dur-
ing treatment, four patients showed increased dyskinesia after 
treatment. We were able to control this increase by decreasing 
levodopa dosage post-treatment. In consequence, it may be pro-
posed that dTMS treatment potentiates the effects of levodopa, 
which in some cases may lead to a decrease in the necessary 
levodopa dose and may control the medication’s complications. 
No matter how suggestive these results may seem, a placebo-
controlled, double blind study should be performed, specially 
designed to determine the efficacy of treatment in non-motor 
symptoms and to assess the possibility that treatment potentiates 
levodopa effects.
The present study has several limitations; it is a retrospective 
evaluation of clinical efficacy, which means it is a compilation of 
45 clinical cases on the effects of dTMS for the treatment of PD 
symptoms. Thus, there was no control group to measure the pla-
cebo effect and therefore it was not “blinded.” This lack of placebo 
control is important. Previous studies have shown that significant 
dopamine release may occur when the declared probability of 
receiving active treatment was above 75%, concluding that the 
strength of belief of improvement can directly modulate dopa-
mine release in patients with PD (41). Placebo responses in PD 
have been reported with a magnitude between 9 and 59% of that 
of the active drug group (42), or 7–10% of symptom relief (43), 
as well as subjective and short lasting, not measured consistently 
by currently used scales (44). Although the present study does 
not have a placebo control group, the treatment with LF rTMS of 
motor cortex has been shown to be effective against placebo in a 
series of randomized placebo-controlled clinical trials reviewed 
by Zhu and colleagues (22). The above placebo-controlled studies 
were designed to assess improvements in motor symptoms using 
UPDRS and were not designed to test non-motor symptoms, 
which according to the present study, may also show improve-
ments in response to treatment.
The SCOPA, MDS-UPDRS, and TINETTI scales used here are 
widely accepted and used in previous studies. The multivariate 
analysis showed correlations between initial values of the scales 
used (MDS-UPDRS, SCOPA, TINETTI) and disease severity and 
years of disease, as well as a correlation between ADL, SCOPA, 
and depression. All those correlations indirectly validate the 
scales used, as such correlations are expected; for example, ADL 
should correlate with depression, and motor exploration should 
correlate with disease severity. Expected correlations were also 
found between disease severity and years with disease, in addition 
to a correlation between ADL, SCOPA, and depression.
A few interesting results were found using the Spearman test. 
First, there was a correlation between physical activity and both 
the score in HDRS at the END and the difference (improvement) 
in the total SCOPA score. By contrast, gender or physical activ-
ity did not correlate neither with disease severity or treatment 
results, whereas patients who exercise may improve more in 
autonomic symptoms and end treatment with greater improve-
ments in depression.
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An issue that cannot be readily assessed in the present study 
is the duration of the improvements. The present results suggest 
that benefits from treatment last for at least 30 days. However, 
a placebo-controlled study is required to assess the duration of 
dTMS effects in PD.
In conclusion, dTMS is a strong predictor of improvements 
in PD symptoms. In our cohort of 45 patients, dTMS treatment 
induced significant improvements in motor and non-motor 
symptoms, ADL, gait, posture, balance, risk of fall, gait speed, 
autonomic and depressive symptoms, as well as a 42% increase 
in ON hours per day. Improvements were independent of 
subjacent depression. These findings suggest that dTMS may be 
an effective add-on for the treatment of PD. A placebo-controlled 
trial analyzing the effects of dTMS on these symptoms need 
follow this study to demonstrate the efficacy of dTMS in PD 
and possible synergic effects with concomitant dopaminergic 
treatment.
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